01—Abstract
Summary
Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Teva Pharmaceutical Industries Ltd. reported in this Form 8-K, filed October 29, 2026, that its Board of Directors elected Dr. David J.
Brailer as a director at a meeting held on October 27, 2026. His service begins November 3, 2026 and runs until Teva's 2027 annual meeting of shareholders. The Board determined that he is independent under the New York Stock Exchange listing rules, and he is expected to serve on the Human Resources and Compensation Committee and the Compliance Committee.
Dr. Brailer's background includes serving as Chairman and Chief Executive Officer of medem.ai since 2024, Founder and Executive Chairman of Health Evolution since 2010, and Founder and Managing Partner of Health Evolution Partners since 2007. He was Chief Health Officer of The Cigna Group from 2022 to 2026 and also its Chief Transformation Officer from 2024 to 2026. He previously sat on the boards of Prolacta Bioscience, Inc. (2012 to 2023) and Walgreens Boots Alliance, Inc. (2012 to 2021).
He has declared in writing that he has the required skills, expertise and time to serve as a director under the Israeli Companies Law, 5759-1999. The filing states that Dr. Brailer will receive the same compensation as Teva's other non-executive directors, as described in the proxy statement filed March 31, 2026. It also reports no arrangements or understandings under which he was elected, no material interest in a related party transaction requiring disclosure under Item 404(a) of Regulation S-K, and no family relationships with any director or executive officer.
02—Key points
Key Highlights
- Dr. David J. Brailer was elected to Teva's Board of Directors on October 27, 2026, effective November 3, 2026, serving until the 2027 annual meeting of shareholders.
- The Board determined Dr. Brailer is independent under New York Stock Exchange listing rules.
- He is expected to serve on Teva's Human Resources and Compensation Committee and Compliance Committee.
- Dr. Brailer most recently served as Chief Health Officer (2022 to 2026) and Chief Transformation Officer (2024 to 2026) of The Cigna Group.
- He currently chairs and leads medem.ai as Chairman and Chief Executive Officer (since 2024) and is Founder and Executive Chairman of Health Evolution.
- His director compensation will match that of Teva's other non-executive directors, as described in the March 31, 2026 proxy statement.
- The filing reports no related party transactions requiring disclosure and no family relationships with Teva directors or executive officers.
03—Questions
Frequently Asked Questions
When does Dr. Brailer's board service begin and how long does it last?
The Board elected him on October 27, 2026, effective November 3, 2026, to serve until Teva's 2027 annual meeting of shareholders.
Is Dr. Brailer considered independent?
Yes. The Board determined that he qualifies as an independent director under the New York Stock Exchange listing rules.
What committees will Dr. Brailer serve on?
He is expected to serve on the Human Resources and Compensation Committee and the Compliance Committee of the Board.
How will Dr. Brailer be compensated?
He will receive the same compensation as Teva's other non-executive directors, as described in the company's definitive proxy statement filed March 31, 2026.
Were there any special arrangements or conflicts tied to his appointment?
The filing states there are no arrangements or understandings between Dr. Brailer and any other persons under which he was elected, no material interest in a related party transaction requiring disclosure under Item 404(a) of Regulation S-K, and no family relationships with any Teva director or executive officer.
04—Continue